Development of extra-musculoskeletal manifestations in upadacitinib-treated patients with psoriatic arthritis or axial spondyloarthritis
Arthritis & Rheumatology 2024. Epub ahead of print doi: 10.1002/art.43069
Poddubnyy et al. analysed five clinical trials to evaluate extra-musculoskeletal manifestations (EMMs) like uveitis, IBD, and psoriasis in patients treated with UPA. They observed low incidences across PsA, r-axSpA, and nr-axSpA. Numerically, uveitis rates were lower in
UPA-treated patients than in those receiving placebo, particularly in r-axSpA.
This study detailed the evaluation of EMM development in patients receiving UPA 15 mg compared to placebo or adalimumab (PsA only). It aimed to assess adverse event rates, distinguishing prior history and new onset of EMMs to inform clinical decisions on spondyloarthritis treatments.
Keywords:
